The mission of Human Genome Sciences is to discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs.
Clinical Development Pipeline
The HGS clinical development pipeline includes drugs to treat hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. The Company’s primary focus is rapid progress toward the commercialization of our two lead products, Albuferon for hepatitis C, and LymphoStat-B for lupus. We have entered into collaboration agreements with two of the world’s leading pharmaceutical companies for the co-development and co-commercialization of these products. Our Albuferon collaborator is Novartis. Our LymphoStat-B collaborator is GlaxoSmithKline. We expect both Albuferon and LymphoStat-B to advance to Phase 3 clinical trials in 2006.
In June 2006, HGS announced that the U.S. Government has exercised its option under an existing contract to purchase 20,000 doses of ABthrax, for the treatment of anthrax disease. Under the contract, we will also complete the additional laboratory and clinical testing required to support the filing of a Biologics License Application with the U.S. Food and Drug Administration, and to support the use of ABthrax in the event of an emergency prior to FDA licensure. Other HGS compounds in clinical development include our three TRAIL receptor antibodies for the treatment of hematopoietic and solid malignancies, and our antibody to the CCR5 receptor for the treatment of HIV/AIDS.
We concentrate our internal product development efforts on new antibody drugs discovered through genomics-based research, and on new long-acting versions of existing protein drugs created using our albumin fusion technology. We rely on collaborations for the development of other products discovered using HGS technology, including small molecule drugs, additional protein and antibody drugs, gene therapy products and diagnostic products.
HGS manufactures its own drugs for preclinical studies and clinical trials. We have completed the construction of a large-scale manufacturing facility to increase our capacity for protein and antibody drug production to support the clinical progress and eventual commercialization of our product candidates. We expect to complete the commissioning and validation of this facility in the second half of 2006.
Senior Management Team
HGS has assembled a highly capable management team with many years of broad-ranging experience. A Management Committee works closely with our Board of Directors, which is chaired by Argeris N. Karabelas, PhD., to set the Company’s strategy and guide its progress toward commercialization. Members of the Management Committee include: H. Thomas Watkins, President and Chief Executive Officer; James H. Davis, Ph.D., J.D., Executive Vice President and General Counsel; Barry A. Labinger, Executive Vice President and Chief Commercial Officer; David C. Stump, M.D., Executive Vice President, Research and Development; Timothy C. Barabe, Senior Vice President and Chief Financial Officer; Susan Bateson, Senior Vice President, Human Resources; and Curran M. Simpson, Senior Vice President, Operations.
HGS was founded in 1992 and is based in Rockville , Maryland , with approximately 880 employees. The Company’s common stock has been traded publicly since 1993 and is listed on the Nasdaq National Market System under the ticker symbol HGSI .